featured
Tepotinib in NSCLC With MET Exon 14 Skipping Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tepotinib in Non–Small-Cell Lung Cancer With MET Exon 14 Skipping Mutations
N. Engl. J. Med 2020 May 29;[EPub Ahead of Print], PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, S Viteri, H Senellart, J Van Meerbeeck, J Raskin, N Reinmuth, P Conte, D Kowalski, BC Cho, JD Patel, L Horn, F Griesinger, JY Han, YC Kim, GC Chang, CL Tsai, JC Yang, YM Chen, EF Smit, AJ van der Wekken, T Kato, D Juraeva, C Stroh, R Bruns, J Straub, A Johne, J Scheele, JV Heymach, X LeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.